Previous Close | 18.09 |
Open | 18.41 |
Bid | 18.75 x 1200 |
Ask | 19.10 x 3000 |
Day's Range | 17.83 - 19.03 |
52 Week Range | 9.59 - 73.03 |
Volume | |
Avg. Volume | 1,710,908 |
Market Cap | 1.284B |
Beta (5Y Monthly) | 1.93 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.23 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.23 |
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Editas (EDIT) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates. Focus remains on the lead candidate, EDIT-101.
Shares of Editas Medicine (NASDAQ: EDIT) were rocketing more than 13% higher in late-afternoon trading on Wednesday, and it was little wonder. The company scored twin beats in its latest set of quarterly results, with one line item in particular being a standout. The genome editing company's revenue was $6.3 million.